Consolidation & Competition in the Life Sciences
The recent merger of Amersham Life Sciences and Pharmacia Upjohn's Pharmacia Biotech creates the biggest player in the research-based biotechnology industry, with combined pro forma sales of $700 million. Will the deal lead to a wave of consolidation in the industry, as suppliers try to keep up with fewer, bigger, and ever more biotech-driven big pharma customers?
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.